Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma

“…To surpass the treatment with sorafenib alone for advanced HCC, new treatments have been developed in recent years [2,5,6]. Histone deacetylase inhibitor resminostat plus sorafenib was safe and showed early signs of efficacy for advanced HCC patients progressing on sorafenib-only treatment [5].…”

“…Histone deacetylase inhibitor resminostat plus sorafenib was safe and showed early signs of efficacy for advanced HCC patients progressing on sorafenib-only treatment [5]. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin achieved favorable overall survival when compared with sorafenib alone for advanced HCC patients [6].…”

Epigenetics in liver disease: from biology to therapeutics

“…116 A recent phase I/II clinical trial of resminostat in 57 patients with HCC and radiological progression on sorafenib treatment was recently reported; median time to progression and overall survival were 6.5 and 8.0 months for combination therapy. 117 The results from resminostat monotherapy were dismal, but suggest that it may restore sensitivity to sorafenib, and be a potential therapeutic option. 117 No safety issues were reported in this study, although the most common adverse events were GI upset, thrombocytopenia and fatigue.…”

“…117 The results from resminostat monotherapy were dismal, but suggest that it may restore sensitivity to sorafenib, and be a potential therapeutic option. 117 No safety issues were reported in this study, although the most common adverse events were GI upset, thrombocytopenia and fatigue. Another prior phase I/II clinical trial of belinostat monotherapy for advanced HCC reported disappointing progression-free survival 2.6 months and overall survival of 6.6 months.…”

Looking Beyond Sorafenib to Treat Advanced Hepatocellular Carcinoma

“…However, this data does justify conducting a randomized controlled trial comparing resection with current standard of care to assess inclusion of liver resection as part of recommendations for treating advanced HCC. The second study by Bitzer et al 10 explored the role of resminostat, a new generation histone deacetylase (HDAC) inhibitor. The study was a multi-center, openlabel, uncontrolled, non-randomized, parallel group phase I/II study of resminostat with and without sorafenib for the treatment of hepatocellular carcinoma that had progressed radiologically despite at least 8 weeks primary treatment with sorafenib.…”